ArticleFrontiers in immunology2026
Associations of polymorphisms in the myeloid immunoregulatory receptor gene MRC1 with expression and prognosis in acute myeloid leukemia.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) shows substantial biological and clinical heterogeneity that extends beyond leukemia-intrinsic genetic alterations. MRC1, which encodes the myeloid receptor CD206, has been linked to monocytic differentiation and immunoregulatory states in AML. We investigated whether the MRC1 variants rs691005 and rs2253120 are associated with AML occurrence, development and prognosis. Methods: We genotyped rs691005 and rs2253120 in 335 patients with AML and 326 healthy controls. Their associations with AML susceptibility, cytogenetic abnormalities, risk stratification, complete remission after two treatment cycles, and overall survival (OS) were examined under co-dominant, dominant, and recessive models. Independent prognostic effects were assessed using multivariable Cox regression. The relationship between SNP and MRC1 expression was evaluated using GTEx eQTL data and genotype-stratified expression measurements in primary AML bone marrow CD34 Results: Neither variant was associated with AML susceptibility, cytogenetic abnormalities, or early remission. rs691005 was associated with adverse risk stratification and showed a nominal association with shorter OS in Kaplan-Meier analysis. rs2253120 AA homozygosity was associated with improved OS after multivariable adjustment and was linked to lower MRC1 expression in GTEx and primary AML samples. Higher MRC1 expression was associated with poorer OS in TCGA-LAML. Virtual MRC1 knockdown revealed exploratory enrichment patterns related to myeloid differentiation, adhesion, cytokine production, and immune regulation. Conclusions: MRC1 rs691005 was linked to adverse risk stratification and shorter OS, whereas rs2253120 AA homozygosity was independently associated with better OS and lower MRC1 expression. These findings support a potential role for inherited variation at the MRC1 locus in the clinical and immune heterogeneity of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.